Rockville-Based CRO Emmes Groups’ OptymEdge launch the first dedicated ophthalmology clinical trial platform at ARVO

Wisconsin, US; May 14, 2025: OptymEdge – part of the Emmes Group – has unveiled a major enhancement to its ophthalmology services with the launch of the clinical research industry’s first technology platform dedicated solely to ophthalmology trials. The platform launch is part of a wider rollout of technology-driven service enhancements and was soft-launched at ARVO 2025, initially featuring BCVA (Best Corrected Visual Acuity), with additional assessments to be introduced as development progresses.

OptymEdge has long-standing expertise in visual function endpoints and certification and is leveraging this experience to reimagine and streamline processes across complex ophthalmology trials.

Demonstrated live at ARVO, Phase 1 of the platform introduction features a dedicated eSource solution for patient data capture. Future phases will introduce an AI-augmented imaging system for trial image reading and a digital site network map encompassing OptymEdge’s global trial network.

Developed specifically for ophthalmology trials, the new eSource platform is designed to replace outdated manual BCVA data entry methods, minimizing human error and enhancing data integrity. In addition to digital data capture, the platform provides step-by-step guidance for BCVA and visual function workflows, helping reduce examiner variability and streamline trial operations. The platform will be fully compatible with Electronic Data Capture (EDC) systems, enabling secure, automated data transfer with no added administrative burden.

In the coming months, OptymEdge will launch its global site network and introduce reading center services as part of its expanded offering. These additions will strengthen OptymEdge’s end-to-end ophthalmology trial capabilities by improving site visibility for sponsors and enabling standardized, high-quality image grading and data review across studies.

Saqib Parkar, Managing Director at OptymEdge, said: “For over 30 years, we’ve been at the forefront of BCVA certification in ophthalmic clinical trials. We identified a clear opportunity to improve data quality, consistency, and efficiency by developing purpose-built technology platforms from the ground up. Our new eSource platform addresses long-standing challenges in manual BCVA data collection and represents a pivotal step in our evolution into a comprehensive ophthalmic research partner. As we expand beyond BCVA into additional ophthalmology endpoints, we remain committed to delivering greater standardization, scalability, and value through integrated digital solutions.”

About OptymEdge

OptymEdge is a partner you can trust. The company develops proven solutions for training and certification of Visual Function Examiners and Visual Acuity Rooms. OptymEdge partners with study teams to deliver visual function certification that ensures a high level of quality and consistency for ophthalmic clinical trial data.

The Early Treatment Diabetic Retinopathy Study (ETDRS) protocols, developed by the National Eye Institute (NEI), serve as a global guide for visual acuity standardization. These protocols provide a foundation that OptymEdge customizes to meet the specific needs of individual clinical trials. OptymEdge’s experience and expertise stem from being the largest and longest-standing certification organization in the industry, having pioneered visual acuity certification from its inception.

OptymEdge’s services are synonymous with delivering the highest levels of quality and standardization in ophthalmic clinical trial data, supported by:

• Over 1,500 sites certified worldwide since 1995
• Experience spanning Phase I through post-marketing trials
• Deep expertise in clinical ophthalmology, optometry, and clinical research

Visit www.optymedge.com for more information.